These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19385713)

  • 21. Review. Clinical pharmacokinetics of bortezomib.
    Levêque D; Carvalho MC; Maloisel F
    In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
    Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
    Moreau P; Coiteux V; Hulin C; Leleu X; van de Velde H; Acharya M; Harousseau JL
    Haematologica; 2008 Dec; 93(12):1908-11. PubMed ID: 18768528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
    Utecht KN; Kolesar J
    Am J Health Syst Pharm; 2008 Jul; 65(13):1221-31. PubMed ID: 18574011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
    Williamson MJ; Silva MD; Terkelsen J; Robertson R; Yu L; Xia C; Hatsis P; Bannerman B; Babcock T; Cao Y; Kupperman E
    Mol Cancer Ther; 2009 Dec; 8(12):3234-43. PubMed ID: 19934276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
    Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Jackson G; Einsele H; Moreau P; Miguel JS
    Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
    Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
    J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omeprazole disposition in children following single-dose administration.
    Kearns GL; Andersson T; James LP; Gaedigk A; Kraynak RA; Abdel-Rahman SM; Ramabadran K; van den Anker JN
    J Clin Pharmacol; 2003 Aug; 43(8):840-8. PubMed ID: 12953341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
    Hunfeld NG; Mathot RA; Touw DJ; van Schaik RH; Mulder PG; Franck PF; Kuipers EJ; Geus WP
    Br J Clin Pharmacol; 2008 May; 65(5):752-60. PubMed ID: 18241283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
    Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
    Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
    Tsimberidou AM; Lewis N; Reid T; Burris H; Urban P; Tan EY; Anand S; Uehara C; Kurzrock R
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1507-16. PubMed ID: 21499896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.